Minovia Therapeutics
Biotechnology Research • 
Haifa, Haifa District, Israel • 21-50 Employees
Company overview
| Headquarters | Haifa, Haifa District, Israel |
| Phone number | +972747039954 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Rare Diseases, Cell Therapy, Mitochondrial Dysfunction, Mitochondria, Mitochondrial Diseases, Mitochondrial Augmentation |
| Founded | 2012 |
| Employees | 21-50 |
| Socials |
Key Contact at Minovia Therapeutics
Maayan Portnoy
Director Of Quality And Analytical Development
Minovia Therapeutics Email Formats
Minovia Therapeutics uses 3 email formats. The most common is {first initial} (e.g., j@minoviatx.com), used 45.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial} | j@minoviatx.com | 45.5% |
{first name} | john@minoviatx.com | 45.5% |
{first name}.{last name} | john.doe@minoviatx.com | 9.1% |
About Minovia Therapeutics
Minovia is a clinical stage company focused on the development and application of mitochondrial cell therapies for patients suffering mitochondrial dysfunction. Mitochondrial Augmentation Technology (MAT) is a cell therapy platform where an off-the-shelf allogeneic isolated mitochondria are developed as cryopreserved, healthy and functional, energy producing organelles and used to augment various cell types to be used as therapeutics products. The lead product, MNV-201 consists of autologous hematopoietic stem and progenitor cells (HSPCs) augmented ex vivo with healthy mitochondria. MNV-201 is currently in clinical trial for Pearson Syndrome and in Pre-clinical stage for Myelodysplastic Syndrome (MDS) indicating encouraging clinical and pre-clinical proof-of-concept for both primary mitochondrial diseases and age-related bone marrow failures. In Minovia we developed novel mitochondria-based biomarkers that allows us to stratify patients according to their "MitoScore". Minovia is establishing a novel aspect of cell therapy quality focusing on mitochondrial science, developing robust analytical methods to measure cellular mitochondrial function, as well as modalities to rescue mitochondrial dysfunction in different cell therapies.
Minovia Therapeutics revenue & valuation
| Annual revenue | $2,224,430 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $7,200,000 |
| Total funding | $350,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Minovia Therapeutics has 13 employees across 7 departments.
Departments
Number of employees
Minovia Therapeutics Tech Stack
Discover the technologies and tools that power Minovia Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
WordPress plugins
Hosting
Reverse proxies
JavaScript libraries
Form builders
Programming languages
Miscellaneous
Blogs
Widgets
JavaScript libraries
Georgia
United Kingdom
United States
Australia
Belgium
Frequently asked questions
4.8
40,000 users
